MedHija LLC has made a great invention in finding out an effective solution to a man’s infertility problem specifically to primary testicular failure.
Prolistem® is a new treatment strategy that has been developed by Dr. Abuelhija in New York for Azoospermia patients and this treatment is dedicated to changing a prevalent attitude that Azoospermia is untreatable. Prolistem® is the third generation of SpermHope® treatment, the new kit has improved formula and stronger effect to increase the success chances for non obstructive azoospermia patients.
Prolistem® is the outcome of extensive male fertility research, as well as animal model research. All of this research has led to development of the Prolistem® treatment, which is based on a better understanding of spermatogenesis. Prolistem® is based on a new concept of testicular cells’ behavior that furthers the understanding of sperm production and the mechanisms of hormonal actions. Prolistem® is a trademark of Med-Hija LLC (DOS ID #: 4836543) (Patented Formula).
Prolistem® formula is an all-natural supplement to renew testicular cells’ division. Prolistem® is designed to enhance the fertility of men with non-obstructive azoospermia.
Dr. Abuelhija has been involved in male fertility studies since 2004, starting with the effect of cytokines and growth factors on the spermatogenesis in mice and humans, as well as in vitro cultures of germ cells and the effects of radiation on spermatogenesis recovery in rats. Dr. Abuelhija is the author and co-author of more than 15 scientific articles, abstracts, and book chapters and specializes in non-obstructive azoospermia.